Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia Long-term follow-up evaluates bone marrow recovery and potential delayed kidney and liver toxicities following Actimab-A plus intensive salvage...
Covered in this story
Call it yourself
No calls on $ASH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ashland →Dalsna Finance is currently tracking 5 stories mentioning Ashland, the earliest published 4 Nov 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.